Q-omics provides the consensus-scored BTBD6 profile across patient tissues and cancer cell-line models. BTBD6 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, BTBD6 is differentially expressed in 11, with the highest sampling consensus in LIHC. Additionally, BTBD6 RNA expression shows 17,593 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, LIHC, and ACC as cancer lineages where BTBD6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BTBD6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BTBD6 survival associations across molecular data types. BTBD6 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BTBD6 RNA expression–survival associations across cancer types. High BTBD6 expression shows unfavorable associations in UVM, ACC and PRAD, but favorable associations in PAAD, KIRC and BRCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for BTBD6 RNA expression.
This table summarizes BTBD6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for BTBD6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BTBD6 shows lower tumor expression in BRCA and KIRP and higher tumor expression in LIHC, STAD, LUSC and CHOL. The LIHC box plot shows higher BTBD6 RNA expression in tumor versus normal tissue (log2 FC = +0.940, t-test p < 0.001).
This table shows molecular features associated with BTBD6 in patient tissues and cancer cell lines. In patient samples, BTBD6 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, BTBD6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
